Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
AstraZeneca,Benralizumab,"Eosinophilic asthma, ACT and >300 cells/ul eosinophil count criteria (widening access)",Benralizumab,Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
